The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug


Gene therapy firm bluebird bio can move forward with a study designed to test the drug lovo-cel in pediatric patients with sickle-cell disease

Previous Floats, 10-year Treasuries and real interest rates: Crow Holdings' Mark Roberts discusses state of the market, 2023 outlook
Next Chef Edward Lee reveals the motivation behind Nami, his new Korean steakhouse